Replies to post #406697 on Amarin Corp Plc (AMRN)

[rosemountbomber]

Thanks for posting GG. A shame Denner wasn't in control at the time of R-I readout. Despite the questions as to whether there has ever been in any interest by BP in Amarin, I can't believe the company couldn't have been sold at that time. Maybe not for what some pie-in-the-sky believers (especially here on this board at the that time) but we should have been able to fetch in the neighborhood of 4 to 8 billion, giving a wide range.

[swg_tdr]

ggwpq, also article on skinny WOW

Zachary Brennan
Senior Editor
The US Solicitor General is calling on the Supreme Court to take up a fiercely debated case that could have a chilling effect on generic drug companies’ willingness to bring their copycats to market under so-called “skinny” labels, meaning the generic can only be approved for some of the reference product’s indications.

The case in question relates to GSK’s win over Teva in a long-running battle over the generic giant’s skinny label for GSK’s beta-blocker Coreg (carvedilol). At the time in 2007, Teva’s generic label first included two of the three Coreg indications, but Teva did not initially win approval for the third indication for congestive heart failure.